RT Journal Article
T1 Gut Microbiota Signatures with Potential Clinical Usefulness in Colorectal and Non-Small Cell Lung Cancers
A1 Tesolato, Sofía
A1 Vicente Valor, Juan
A1 Paz Cabezas, Mateo
A1 Gómez Garre, Dulcenombre
A1 Sánchez González, Silvia
A1 Ortega Hernández, Adriana
A1 De La-Serna Esteban, Sofía Cristina
A1 Domínguez Serrano, María Inmaculada
A1 Dzyakova, Jana
A1 Rivera, Daniel
A1 Jarabo Sarceda, José Ramón
A1 Gómez Martínez, Ana María
A1 Hernando Trancho, Florentino
A1 Torres García, Antonio José
A1 Iniesta Serrano, María Pilar
A2 Ryota Niikura, 
AB The application of bacterial metagenomic analysis as a biomarker for cancer detection is emerging. Our aim was to discover gut microbiota signatures with potential utility in the diagnosis of colorectal cancer (CRC) and non-small cell lung cancer (NSCLC). A prospective study was performed on a total of 77 fecal samples from CRC and NSCLC patients and controls. DNA from stool was analyzed for bacterial genomic sequencing using the Ion Torrent™ technology. Bioinformatic analysis was performed using the QIIME2 pipeline. We applied logistic regression to adjust for differences attributable to sex, age, and body mass index, and the diagnostic accuracy of our gut signatures was compared with other previously published results. The feces of patients affected by different tumor types, such as CRC and NSCLC, showed a differential intestinal microbiota profile. After adjusting for confounders, Parvimonas (OR = 53.3), Gemella (OR = 6.01), Eisenbergiella (OR = 5.35), Peptostreptococcus (OR = 9.42), Lactobacillus (OR = 6.72), Salmonella (OR = 5.44), and Fusobacterium (OR = 78.9) remained significantly associated with the risk of CRC. Two genera from the Ruminococcaceae family, DTU089 (OR = 20.1) and an uncharacterized genus (OR = 160.1), were associated with the risk of NSCLC. Our two panels had better diagnostic capacity for CRC (AUC = 0.840) and NSLC (AUC = 0.747) compared to the application of two other published panels to our population. Thus, we propose a gut bacteria panel for each cancer type and show its potential application in cancer diagnosis.
PB MDPI
SN 2227-9059
YR 2024
FD 2024-03-21
LK https://hdl.handle.net/20.500.14352/102675
UL https://hdl.handle.net/20.500.14352/102675
LA eng
NO Tesolato, S.; Vicente-Valor, J.; Paz-Cabezas, M.; Gómez-Garre, D.; Sánchez-González, S.; Ortega-Hernández, A.; de la Serna, S.; Domínguez-Serrano, I.; Dziakova, J.; Rivera, D.; et al. Gut Microbiota Signatures with Potential Clinical Usefulness in Colorectal and Non-Small Cell Lung Cancers. Biomedicines 2024, 12, 703. https://doi.org/10.3390/ biomedicines12030703
NO Ministerio de Economía y Competitividad
NO Unión Europea
DS Docta Complutense
RD 21 ago 2024